Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 601–700 of 3,704
Silvestri, A., Gil‐Gómez, A., Vitale, M., Braga, D., Demitri, C., Brescia, P., Madaghiele, M., Spadoni, I., Jones, B., Fornasa, G., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101235 · Cited by 31
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 29
“Clinical trials have shown significant weight loss even reaching 20.9% mean change in body weight or mean weight reduction of 11.2 kg with the 15 mg dose of tirzepatide (Frias, et al., 2021; Jastreboff et al., 2022).”
BackgroundInfluentialSeeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“Clinical studies have shown that tirzepatide induces an average of 21.5% weight loss in humans with obesity, with 15% weight loss in obese patients diagnosed with diabetes ( 152 ).”
BackgroundInfluentialRecent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
“A high dose of tirzepatide (15 mg once weekly by subcutaneous injection: Mounjaro and Zepbound ) typically reduced body weight by about 20% during treatment periods up to 2 years in overweight and obese adults who did not have T2DM (SURMOUNT-1 and 3) [31,32].”
MethodDash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
“The receptor for GLP-1 is widely expressed and contributes to pleiotropic metabolic benefits of GLP-1RAs, including reduction in triglyceride-rich lipoproteins, natriuresis and blood pressure reduction 59 – 61 (Figure 3).”
InfluentialObesity wars: hypothalamic sEVs a new hope
Mukherjee, S., Diéguez, C., Fernø, J., & López, M. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.04.006 · Cited by 26
Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management
Powell, J., & Taylor, J. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.014 · Cited by 27
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
“Beyond the glucose-lowering benefits, significant effects on weight reduction were shown in trials with semaglutide (GLP-1RA) [39–42] and tirzepatide (GIP/ GLP-1 RA) [43–48] in people with or without T2D.”
BackgroundCurrent and Future Treatments of Vascular Cognitive Impairment
Ip, B. Y. M., Ko, H., Lam, B. Y. K., Au, L. W. C., Lau, A. Y. L., Huang, J., Kwok, A. J., Leng, X., Cai, Y., Leung, T. W. H., et al. (2024) · Stroke · doi:10.1161/strokeaha.123.044174 · Cited by 31
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Ali, M. M., Parveen, S., Williams, V. R., Dons, R. F., & Uwaifo, G. I. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100341 · Cited by 42
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
Verhey, J. T., Austin, R. P., Tarabichi, S., Paul, B., Deckey, D. G., Christopher, Z. K., Spangehl, M. J., & Bingham, J. S. (2025) · The Journal of Arthroplasty · doi:10.1016/j.arth.2025.03.012 · Cited by 28
Verde, L., Lucà, S., Cernea, S., Sulu, C., Yumuk, V., Jenssen, T. G., Savastano, S., Sarno, G., Colao, A., Barrea, L., et al. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00500-9 · Cited by 32
Lopez‐Yus, M., García-Sobreviela, M. P., del Moral, R., & Arbonés-Mainar, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087468 · Cited by 27
“On the other hand, some pharmacological strategies targeting the energy balance regulatory system are now reaching clinically relevant reductions in body weight [6,7].”
BackgroundAnti-obesity drugs’ side effects: what we know so far
Lenharo, M. (2023) · Nature · doi:10.1038/d41586-023-03183-3 · Cited by 27
Lifestyle Interventions for Obesity in the Era of GLP-1 Receptor Agonists
Ard, J. D., Lewis, K. H., & Moore, J. B. (2024) · JAMA · doi:10.1001/jama.2024.7062 · Cited by 26
Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H. (2025) · European Heart Journal Open · doi:10.1093/ehjopen/oeaf117 · Cited by 24
“9,11 The results are consistent between these current analyses of SURMOUNT-5 data and those by Wong et al. 13,14 particularly in the treatment effect of tirzepatide vs. semaglutide on CVD risk reduction.”
Pharmacological Treatment of Obesity in Older Adults
Žižka, O., Haluzík, M., & Jude, E. B. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01150-9 · Cited by 23
“The ratio of total fat mass to total lean mass decreased more with tirzepatide (from 0.93 at baseline to 0.70 at week 72) compared with placebo (from 0.95 to 0.88) [71].”
BackgroundInfluentialDual gut hormone receptor agonists for diabetes and obesity
Bass, J., Tschöp, M. H., & Beutler, L. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167952 · Cited by 21
“Recently, the gastric inhibitory polypeptide receptor/GLP1R (GIPR/GLP1R) co-agonist, tirzepatide, became the first polyagonist approved for the treatment of T2DM; it induces a staggering 22% average weight loss in patients with obesity (1).”
BackgroundFitch, A., Malhotra, S., & Conroy, R. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100110 · Cited by 32
“The dual GLP-1R and glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide showed significant weight loss in patients with polygenic obesity but evidence of its efficacy and safety in monogenic or syndromic obesity has not been demonstrated [166,176].”
BackgroundSemaglutide for weight loss: unanswered questions
Tzoulis, P., & Baldeweg, S. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1382814 · Cited by 30
“…who would bene fi t more from alternative pharmacotherapies, such as dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist (30) or combination of GLP-1 agonist an amylin analogue (31) or triple GLP-1, GIP and glucagon receptors agonist (32), or endoscopic procedures or…”
BackgroundJakicic, J. M., Apovian, C. M., Barr‐Anderson, D. J., Courcoulas, A. P., Donnelly, J. E., Ekkekakis, P., Hopkins, M., Lambert, M., Napolitano, M. A., & Volpe, S. L. (2024) · Translational Journal of the American College of Sports Medicine · doi:10.1249/tjx.0000000000000266 · Cited by 34
Identification and characterization of human GDF15 knockouts
Gurtan, A. M., Khalid, S., Koch, C., Khan, M. Z., Lamarche, L. B., Splawski, I., Dolan, E., Carrion, A. M., Zessis, R., Clement, M. E., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01135-3 · Cited by 28
Price, S., & Nankervis, A. J. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07849-9 · Cited by 32
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
At the Crossroads of Health and Disease: Consequences of Fat in the Liver
Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 39
Delvadia, P., Dhote, V. V., Mandloi, A. S., Soni, R., & Shah, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00729 · Cited by 29
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
“People with obesity or overweight (without T2DM) showed significant weight loss; 18.4–20.9%, with the 10 mg and 15 mg, along with improvements in cardiometabolic risk factors [118–120].”
InfluentialNovel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis
Kellner, D. A., Dente, E., Tran, V., Welsh, T., Tran, V., Saha, A., Baker, J. F., Elashoff, D. A., & Ranganath, V. K. (2025) · ACR Open Rheumatology · doi:10.1002/acr2.70103 · Cited by 27
“11 Although they are increasingly used in the general population, there is a paucity of data on their clinical effects in patients with RA.”
Sievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 58
“Importantly, individual responses to GBTs vary, and suboptimal outcomes (weight loss ≤ 5 % after 12 weeks of GBT) may warrant a reassessment of treatment strategies [29,136,137].”
Holmbäck, U. C., Grudén, S., Litorp, H., Willhems, D., Kuusk, S., Alderborn, G., Söderhäll, A., & Forslund, A. H. (2022) · Obesity · doi:10.1002/oby.23557 · Cited by 28
“The magnitude of the weight loss may have been less than that achieved with semaglutide and tirzepatide [1,2,31], but it was similar to other oral weight-loss products, as well as liraglutide [32].”
ResultPharmacological targeting of glutamatergic neurons within the brainstem for weight reduction
Schneeberger, M., Brice, N., Pellegrino, K., Parolari, L., Shaked, J. T., Page, K. J., Marchildon, F., Barrows, D., Carroll, T. S., Topilko, T., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00677-8 · Cited by 28
“Measurements of food intake were taken at 1, 2, 4, 8 and 24 hours following injection or infusion for acute studies, and every 24 hours when fed chronically on a HFD. Drug infusions were achieved by means of infusion pump (Harvard Apparatus) attach to glass syringes (Hamilton), with an infusion…”
Psychological and medical treatments for binge-eating disorder: A research update
Hilbert, A. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114267 · Cited by 31
Peterli, R., Hurme, S. A. M., Bueter, M., Grönroos, S., Helmiö, M., & Salminen, P. T. P. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.6254 · Cited by 30
The antiemetic actions of GIP receptor agonism
Borner, T., Jonghe, B. C. D., & Hayes, M. R. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00330.2023 · Cited by 28
Fan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25
Radwan, R. M., Lee, Y. A., Kotecha, P., Wright, D. R., Hernandez, I., Ramon, R., Donahoo, W. T., Chen, Y., Allen, J. M., Bian, J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16318 · Cited by 24
Female obesity: clinical and psychological assessment toward the best treatment
Guglielmi, V., Grave, R. D., Leonetti, F., & Solini, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1349794 · Cited by 44
Lara, C., & Romero‐Gómez, M. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.34 · Cited by 26
Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy
Nicze, M., Dec, A., Borówka, M., Krzyżak, D., Bołdys, A., Bułdak, Ł., & Okopień, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158202 · Cited by 33
Skeletal muscle loss and sarcopenia in obesity pharmacotherapy
Hope, D. C. D., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01041-4 · Cited by 29
“Despite this finding, the ratio of total fat mass to total lean mass decreased more in the tirzepatide group, and physical activity scores were increased 6 .”
Evolving Approaches for Pharmacological Therapy of Obesity
Chao, A. M., Taylor, S. I., Moore, M., Amaro, A., & Wadden, T. A. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031124-101146 · Cited by 30
Karakasis, P., Sagris, Μ., Patoulias, D., Koufakis, T., Theofilis, P., Klisic, A. N., Fragakis, N., El‐Tanani, M., & Rizzo, M. (2024) · Biomedicines · doi:10.3390/biomedicines12112503 · Cited by 24
“Clinical studies have demonstrated that treatment with tirzepatide results in substantial reductions in excess body weight, along with improvements in BP, and decreases in biomarkers associated with inflammation and vascular endothelial dysfunction [94,95].”
A Guideline-Directed Approach to Obesity Treatment
Chao, A. M., Paul, A. M., Hodgkins, J., & Wadden, T. A. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0001 · Cited by 35
Cheah, M. C. C., Crane, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10801-x · Cited by 37
“In the SURMOUNT-1 trial evaluating Tirzeptide for weight loss, the investigators reported a -33.9% fat mass loss but a worrying 10.9% lean mass loss [15].”
InfluentialOstrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 29
Clinical Impact of Tirzepatide on Patients With OSA and Obesity
Wu, J., Chen, C., Tu, W.-L., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Hung, K., Yu, T., et al. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.03.030 · Cited by 26
Singh, V., Sun, J. M., Cheng, S. C., Kwan, A. C., & Velazquez, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03352-y · Cited by 37
“This medication was approved as a weekly subcutaneous injection in 2023 for the treatment of obesity and has been studied through four SURMOUNT RCTs [119–122].”
InfluentialSibal, R., Balamurugan, G., Langley, J., Graham, Y., & Mahawar, K. K. (2025) · Nutrients · doi:10.3390/nu17233659 · Cited by 30
“The dual GIP/GLP-1 agonist tirzepatide in SURMOUNT-1 achieved reductions exceeding 20% in some participants [5], as demonstrated in a 72-week, phase 3 trial enrolling 2539 adults with obesity.”
Dharmaratnam, V. M., Lim, E. K. W., Eng, A. K. H., Chan, W. H., Tan, H. C., Ho, E. T. L., Kovalik, J., Ganguly, S., Tan, J. T. H., Lee, P. C., et al. (2022) · Obesity Surgery · doi:10.1007/s11695-022-06191-w · Cited by 24
“Recent advances in pharmacotherapy have seen several gut-hormone based therapies (such as semaglutide and tirzepatide) showing impressive results in phase 3 trials with average %TWL of 18–22% [11, 12].”
BackgroundA Pathophysiological Intersection of Diabetes and Alzheimer’s Disease
Čater, M., & Hölter, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911562 · Cited by 29
Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
Samuel, S. M., Varghese, E., Kubatka, P., & Büsselberg, D. (2022) · Biomolecules · doi:10.3390/biom12111580 · Cited by 24
“Additionally, administration of the anti-hyperglycemic dosage of TRZD (5 mg, 10 mg, and 15 mg TRZD once weekly) was associated with a significant and sustained reduction in body weight [21].”
BackgroundThe ‘breakthrough’ obesity drugs that have stunned researchers
Prillaman, M. (2023) · Nature · doi:10.1038/d41586-022-04505-7 · Cited by 22
Metabolically Healthy Obesity: Are Interventions Useful?
Mathis, B. J., Tanaka, K., & Hiramatsu, Y. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00494-4 · Cited by 28
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Viggers, R., Rasmussen, N. H., & Vestergaard, P. (2023) · JBMR Plus · doi:10.1002/jbm4.10817 · Cited by 29
Rubio, M. Á., Carreiro, S. M., Sánchez-Pernaute, A., & Ramos-Levi, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102785 · Cited by 28
“…new drugs for the management of obesity, which are currently being evaluated in phase 3 studies, and that have proven to achieve weight loss rates above 20%, will almost reach comparable results to MBS [40–42] and will probably entail significant reductions in the long waiting lists for MBS.”
ResultTargeting the GLP-2 receptor in the management of obesity
Pálsson, T. G., Gilliam‐Vigh, H., Jensen, B. A. H., Jeppesen, P. B., Lund, A., Knop, F. K., & Nielsen, C. K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171210 · Cited by 26
“Interestingly, tirzepatide, a single-molecule compound stimulating both the GLP-1R and the receptor for its ‘sister ’ incretin hormone glucose-dependent insulinotropic polypeptide (GIP), the GIP receptor (GIPR), seems to provide greater weight loss as compared to GLP-1R monoagonism [20].”
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 23
“As such, medications such as tirzepatide, which has a stronger af fi nity for the GIP receptor than the GLP-1 receptor, may be safer in the perioperative period, mitigating the risk of aspiration [46,171].”
InfluentialMonitoring Report: GLP-1 RA Prescribing Trends - September 2024 DataPreprint
Gratzl, S., Rodriguez, P. J., Cartwright, B. M. G., Baker, C., & Stucky, N. L. (2024) · medRxiv · doi:10.1101/2024.01.18.24301500 · Cited by 29
Triple Agonism Based Therapies for Obesity
Goldney, J., Hamza, M., Surti, F., Davies, M. J., & Papamargaritis, D. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00770-z · Cited by 22
“3) [8, 27, 45, 46, 49, 50].”
InfluentialHolding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy
Ahmad, A. I., Garg, S., Jacobs, J., Ansari, Z., Al-Din, T. J., Almomani, A., Valencia, S., Vargo, J., Chatterjee, A., Siddiki, H., et al. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.0027 · Cited by 24
Baker, D. E., Walley, K., & Levien, T. L. (2023) · Hospital Pharmacy · doi:10.1177/00185787221125724 · Cited by 21
RETRACTED: Tirzepatide and exercise training in obesity
Bagherzadeh-Rahmani, B., Marzetti, E., Karami, E., Campbell, B. I., Fakourian, A., Haghighi, A. H., Mousavi, S. H., Heinrich, K. M., Brazzi, L., Jung, F., et al. (2024) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-242134 · Cited by 21
“Tirzepatide injection was administered subcutaneously in the abdomen by a physician once a week using doses of 2.5 mg and 5 mg on a day when the subject did not exercise [25, 26].”
InfluentialRetractedMa, J., Hu, X., Zhang, W., Tao, M., Wang, M., & Lu, W. (2024) · Endocrine · doi:10.1007/s12020-024-03998-8 · Cited by 21
“Additionally, another clinical trial involving obese or overweight patients revealed that Tir-zepatide effectively reduced body weight and improved cardiorenal risk factors, encompassing blood glucose levels, blood pressure, glycated hemoglobin, and albumi-nuria [17].”
Raven, L. M., Brown, C., & Greenfield, J. R. (2024) · Medical Journal of Australia · doi:10.5694/mja2.52170 · Cited by 21
Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn
Murphy, E. E., & Finucane, F. M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01499-2 · Cited by 23
“This implies that obesity is inherently less worthy of treatment than diabetes, contrary to the recognition of obesity as a disease [56] and trivialising the proven clinical bene fi ts of the treatment of obesity [2, 3, 57].”
GIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
“…peptides in one molecule, resulted in weight loss of 15% after four doses over 85 days of administration in obese individuals with a mean BMI of 33.8 kg/m 2 (multiple ascending doses, every fourth week, phase 1 trial). r o The adverse effects were mild-moderate but highly prevalent (70-100”
InfluentialKim, D. D., Hwang, J. H., & Fendrick, A. M. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae055 · Cited by 21
Okuma, H., & Tsuchiya, K. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108699 · Cited by 24
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
“Comparative weight loss outcomes from currently available incretin-hormonal therapies in major clinical trials 16,23,42 .”
Advances in the Insulin–Heart Axis: Current Therapies and Future Directions
Caturano, A., Vetrano, E., Galiero, R., Sardu, C., Rinaldi, L., Russo, V., Monda, M., Marfella, R., & Sasso, F. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810173 · Cited by 28
“The Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) (NCT04184622) recently demonstrated the efficacy of once-weekly tirzepatide in adults who are overweight or obese, achieving up to 20.9% reductions in body weight with 15 mg doses [153,154].”
BackgroundInfluentialDutta, D., Kamrul-Hasan, A. B. M., Nagendra, L., & Bhattacharya, S. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.2.10 · Cited by 23
“4,5 One of the two excluded studies was the post hoc analysis of an included RCT; the other reported an indirect treatment comparison of tirzepatide and semaglutide.”
BackgroundTime to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials
Horn, D. B., Kahan, S., Batterham, R. L., Cao, D., Lee, C. J., Murphy, M., Gonsahn‐Bollie, S., Chigutsa, F., Stefanski, A., & Dunn, J. P. (2025) · Clinical Obesity · doi:10.1111/cob.12734 · Cited by 25
Self-citationMozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Bardóczi, A. B., Matics, Z., Turan, C., Szabó, B., Molnár, Z., Hegyi, P., Müller, V., & Horváth, G. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102119 · Cited by 28
The role of bone in whole-body energy metabolism
Lecka‐Czernik, B., Rosen, C. J., & Napoli, N. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01162-4 · Cited by 35
Ng, C. D., Divino, V. M., Wang, J., Toliver, J. C., & Buss, M. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03340-2 · Cited by 44
“Similarly, in the phase 3, randomized, placebo-controlled SURMOUNT-1 trial, patients without T2DM who were treated with tirzepatide 5 mg, 10 mg, and 15 mg achieved a mean weight loss of − 15.0%, − 19.5%, and − 20.9%, respectively, at 72 weeks (all P 0.001 vs placebo) [23].”
InfluentialLiu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
“77 The most frequently reported adverse effects of GLP-1RAs include nausea, vomiting, and diarrhea, which are dose-dependent and more prevalent with short-acting formulations than with long-acting agents.”
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., le Roux, C. W., Srinath, R., Valderas, E. G., Arad, A. D., Das, S., Dunn, J. P., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00656-2 · Cited by 52
Self-citationHypoxia as a Double-Edged Sword to Combat Obesity and Comorbidities
Wang, R., Sun, Q., Wu, X., Zhang, Y., Xing, X., Lin, K., Feng, Y., Wang, M., Wang, Y., & Wang, R. (2022) · Cells · doi:10.3390/cells11233735 · Cited by 23
How can physical activity facilitate a sustainable future? Reducing obesity and chronic disease
Stensel, D. J. (2023) · Proceedings of The Nutrition Society · doi:10.1017/s0029665123002203 · Cited by 26
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Ma, Z., Jin, K., Yue, M., Chen, X., & Chen, J. (2023) · Journal of Diabetes Research · doi:10.1155/2023/5891532 · Cited by 30
“At the same time, weight loss with tirzepatide was accompanied by a significant improvement in cardiovascular and metabolic risk factors compared to placebo (including waist circumference, systolic and diastolic blood pressure, fasting insulin levels, and blood lipid levels) [17].”
BackgroundCKD therapy to improve outcomes of immune-mediated glomerular diseases
Anders, H., Juarez, G. M. F., Vaglio, A., Romagnani, P., & Floege, J. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad069 · Cited by 25
Cardiorenal syndrome and diabetes: an evil pairing
Méndez, A. B., Vergara, A., Olivella, A., Azancot, M. A., Soriano-Colomé, T., & Soler, M. J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1185707 · Cited by 25
“The central glucose-dependent insulinotropic polypeptide receptor effect of tirzepatide adds to the GLP-1 AR, allowing a more substantial reduction in food intake, leading to a further drop in body weight (98, 99).”
BackgroundGlycogen-fuelled metabolism supports rapid mucosal-associated invariant T cell responses
Cassidy, F. C., Kedia-Mehta, N., Bergin, R., Woodcock, A., Berisha, A., Bradley, B., Booth, E., Jenkins, B. J., Ryan, O. K., Jones, N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300566120 · Cited by 22
Net prices of new antiobesity medications
Hernandez, I., & Sullivan, S. D. (2024) · Obesity · doi:10.1002/oby.23973 · Cited by 22
“GLP1s are highly effective antiobesity agents [1, 2], and in recent trials, they were associated with significant reductions in the incidence of cardiovascular events [ 3].”
BackgroundOertel, M., Ziegler, C. G., Kohlhaas, M., Nickel, A. G., Kloock, S., Maack, C., Sequeira, V., Faßnacht, M., & Dischinger, U. (2024) · Endocrine Connections · doi:10.1530/ec-23-0398 · Cited by 25
“GLP-1 is mainly involved in central appetite regulation, pancreatic function, energy balance and gastric motility (19, 20).”
BackgroundGlucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV
Nguyen, Q., Wooten, D. A., Lee, D., Moreno, M., Promer, K., Rajagopal, A., Tan, M. Z.-W., Tang, M. E., Duren, K., Yin, J. H., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae151 · Cited by 34
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102665 · Cited by 21
Cengiz, A., Wu, C. C., & Lawley, S. D. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16229 · Cited by 20
“Figure 2 predicts the efficacy of 1.7 or 2.4 mg of semaglutide administered less frequently than once-weekly.”
InfluentialBepo, L., Nguyen, O. K., & Makam, A. N. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08961-x · Cited by 20
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
Bhatnagar, P., Ahmad, N. N., Li, X., Coghlan, M., Kaplan, L. M., & Farooqi, I. S. (2025) · Nature Medicine · doi:10.1038/s41591-025-03913-2 · Cited by 20
“%) in people with obesity, with and without type 2 diabetes 2,3 .”
Self-citationVariation in responses to incretin therapy: Modifiable and non-modifiable factors
Austin, G. O., & Tomás, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170181 · Cited by 25
“Moreover, last year a separate study showed that 91% of obese individuals receiving a weekly dose of 15 mg Tirzepatide—a recently developed GLP-1R/GIPR dual agonist, lost 5% of their body mass with 36% of participants on the same dosage losing at least 25% (Jastreboff et al., 2022).”
BackgroundBecetti, I., Bwenyi, E. L., de Araújo, I. E., Ard, J. D., Cryan, J. F., Farooqi, I. S., Ferrario, C. R., Gluck, M. E., Holsen, L. M., Kenny, P. J., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.05.003 · Cited by 29
Chetty, A. K., Rafi, E., Bellini, N. J., Buchholz, N., & Isaacs, D. M. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.010 · Cited by 23
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 27
“Of interest, tirzepatide at once-weekly administration has already been approved for the treatment of obesity [105].”
BackgroundGLP-1 receptor agonists and weight loss in schizophrenia – past, present, and future
Trott, M., Arnautovska, U., & Siskind, D. J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000952 · Cited by 26
Yang, J., Gu, Y., Chen, H., Wang, H., Hong, L., Li, B., & Yang, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1453825 · Cited by 27
Brown, S., Tadros, A. B., Montagna, G., Bell, T., Crowley, F., Gallagher, E. J., & Dayan, J. H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1457363 · Cited by 24
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.